Food and Drug Administration scientists did not support an effort by President Donald Trump's administration to loosen rules on unproven peptide drugs, ABC News reported in a wire story. The summary of that report does not give the number of scientists involved or describe the proposed rules in detail, so this account relies only on the headline and summary available for each report.
The Guardian reported, citing an Associated Press report, that the plan would have given people in the United States easier access to unproven peptide drugs favored by Health Secretary Robert F Kennedy Jr. Its summary said the effort faced fierce pushback from agency scientists.
According to the Associated Press, as summarized by The Guardian, most FDA scientific staff members opposed the plan. The report said that finding rested on six people, and that the scientists had limited input in drafting the policy.
The two accounts agree that FDA scientists opposed the effort. They differ in detail. The ABC News summary states the opposition in a single sentence, while the Guardian and Associated Press summary adds the role of Kennedy, the fact that most staff members opposed the plan, and the limited role scientists played in drafting the policy.
Neither summary states whether the proposal has been adopted, changed or withdrawn, and neither describes a response from the Food and Drug Administration. Further detail on those points was not available in the material used for this story.
Both summaries are brief, and each describes the scientists' position in general terms rather than naming individual officials. Readers seeking the complete reporting can consult the full Guardian article, which carries the Associated Press text.
Sources: ABC News: FDA scientists opposed the Trump administration's effort to ease peptides access; The Guardian: FDA scientists opposed Trump administration’s move to ease peptide access.